Sen­ti Bio of­floads man­u­fac­tur­ing site to Hong Kong PE firm for $38M

San Fran­cis­co-based pre­clin­i­cal biotech Sen­ti Bio­sciences is sell­ing off a man­u­fac­tur­ing fa­cil­i­ty to a pri­vate eq­ui­ty firm that’s spin­ning it in­to a new con­tract man­u­fac­tur­er known as Gene­Fab.

Sen­ti said Thurs­day it will sub­lease its re­cent­ly con­struct­ed, 92,000-square-foot man­u­fac­tur­ing fa­cil­i­ty in Alame­da, CA, to Gene­Fab, which is backed by Celadon Part­ners, a Hong Kong-based pri­vate eq­ui­ty firm. Gene­Fab will al­so ac­quire all of Sen­ti Bio’s chem­istry man­u­fac­tur­ing and con­trol ca­pa­bil­i­ties for $38 mil­lion. The move will give Sen­ti Bio enough run­way to last in­to the fourth quar­ter of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER